SCHEMBL17045221

SCHEMBL17045221

[CH2][C@@H](N)Cc1ccc(C)cc1

nearest known ligand 0.44

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 4/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2A6 P11509 1/20 0.44
AGXT P21549 2/20 0.43
IDO1 P14902 1/20 0.42
SLC6A2 P23975 2/20 0.40
SLC6A3 Q01959 1/20 0.40
SLC6A4 P31645 1/20 0.39
ACHE P22303 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17045209 1.00 TAAR1 (0.44) TAAR1CYP1A2CYP2A6AGXTIDO1
SCHEMBL11068499 0.80 SLC6A4 (0.58) TAAR1CYP1A2CYP2A6AGXTIDO1
SCHEMBL24017125 0.80 TAAR1 (0.48) TAAR1CYP1A2CYP2A6AGXTIDO1
SCHEMBL24017123 0.80 TAAR1 (0.48) TAAR1CYP1A2CYP2A6AGXTIDO1
SCHEMBL22013359 0.80 TAAR1 (0.48) TAAR1CYP1A2CYP2A6AGXTIDO1
SCHEMBL42179 0.78 TAAR1 (0.64) TAAR1CYP2A6SLC6A2SLC6A3SLC6A4
SCHEMBL22873938 0.78 TAAR1 (0.64) TAAR1CYP2A6SLC6A2SLC6A3SLC6A4
SCHEMBL10918313 0.78 IDO1 (0.44) TAAR1CYP1A2CYP2A6AGXTIDO1
SCHEMBL81938 0.78 TAAR1 (0.64) TAAR1CYP2A6SLC6A2SLC6A3SLC6A4
SCHEMBL14040458 0.76 IDO1 (0.48) TAAR1CYP1A2CYP2A6AGXTIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218562-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-07-13 US claimed
US-20210113514-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS., LTD. 2021-04-22 US claimed
US-10888542-B2 Aminocarbonylcarbamate compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2021-01-12 US claimed
US-20200046674-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2020-02-13 US claimed
US-9833432-B2 Aminocarbonylcarbamate compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2017-12-05 US claimed
EP-3110792-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK Biopharmaceuticals Co., Ltd. (KR) 2017-01-04 EP claimed
US-20160303067-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. 2016-10-20 US claimed
US-9403761-B2 Aminocarbonylcarbamate compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-08-02 US claimed
WO-2015130121-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2015-09-03 WO claimed
US-20150246874-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2015-09-03 US claimed
EP-4395763-A1 METHODS AND COMPOSITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE AXSOME THERAPEUTICS (US) 2024-07-10 EP disclosed
US-20230218562-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-07-13 US disclosed
WO-2023034944-A1 METHODS AND COMPOSITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE AXSOME THERAPEUTICS (US) 2023-03-09 WO disclosed
US-20210113514-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS., LTD. 2021-04-22 US disclosed
US-10888542-B2 Aminocarbonylcarbamate compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2021-01-12 US disclosed
EP-3110792-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK Biopharmaceuticals Co., Ltd. (KR) 2017-01-04 EP disclosed
US-20160303067-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. 2016-10-20 US disclosed
US-9403761-B2 Aminocarbonylcarbamate compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-08-02 US disclosed
WO-2015130121-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2015-09-03 WO disclosed
US-20150246874-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2015-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246874-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 TAAR1 79/4885CYP1A2 1175/4885CYP2A6 694/4885
US-10888542-B2 Aminocarbonylcarbamate compounds SLC6A3, SLC6A2, SLC6A4 TAAR1 79/4885CYP1A2 1175/4885CYP2A6 694/4885
US-20160303067-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 TAAR1 79/4885CYP1A2 1175/4885CYP2A6 694/4885
US-20210113514-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 TAAR1 79/4885CYP1A2 1175/4885CYP2A6 694/4885
US-20200046674-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 TAAR1 79/4885CYP1A2 1175/4885CYP2A6 694/4885
US-20230218562-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 TAAR1 79/4885CYP1A2 1175/4885CYP2A6 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.